Allergic contact dermatitis from etofenamate without cross-sensitization to other anthranilic acid derivatives [1]
Journal
Dermatology
Journal Volume
206
Journal Issue
4
Pages
341-342
Date Issued
2003
Author(s)
Abstract
Letters| June 13 2003 Allergic Contact Dermatitis from Etofenamate without Cross-Sensitization to Other Anthranilic Acid Derivatives Topic Article Package: Topic Article Package: Sports Medicine Subject Area: Dermatology , Immunology and Allergy Chia-Yu Chu; Chia-Yu Chu Departments of Dermatology and Search for other works by this author on: This Site PubMed Google Scholar Yen-Liang Chen; Yen-Liang Chen Departments of Dermatology and Search for other works by this author on: This Site PubMed Google Scholar Lie-Jane Lin; Lie-Jane Lin Pharmacy, National Taiwan University Hospital, Taipei, Taiwan, ROC Search for other works by this author on: This Site PubMed Google Scholar Chee-Ching Sun Chee-Ching Sun Departments of Dermatology and Search for other works by this author on: This Site PubMed Google Scholar Dermatology (2003) 206 (4): 341–342. https://doi.org/10.1159/000069949 Article history Published Online: June 13 2003 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Chia-Yu Chu, Yen-Liang Chen, Lie-Jane Lin, Chee-Ching Sun; Allergic Contact Dermatitis from Etofenamate without Cross-Sensitization to Other Anthranilic Acid Derivatives. Dermatology 1 July 2003; 206 (4): 341–342. https://doi.org/10.1159/000069949 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsDermatology Search Advanced Search This content is only available via PDF. 2003Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
SDGs
Other Subjects
anthranilic acid derivative; antiinflammatory agent; arylpropionic acid derivative; benoxaprofen; bufexamac; carbamazepine; carbomer; carprofen; diclofenac; etofenamate; fenamic acid derivative; flufenamic acid; flurbiprofen; indometacin; ketoprofen; meclofenamate sodium; mefenamic acid; nickel sulfate; niflumic acid; nonsteroid antiinflammatory agent; piroxicam; propylene glycol; pyrazolone; pyrazolone derivative; tiaprofenic acid; adult; arthritis; case report; contact dermatitis; cross allergy; cross reaction; drug screening; drug withdrawal; erythema; human; informed consent; letter; male; myalgia; patch test; photoallergy; photosensitivity; priority journal; pruritus; rheumatic disease; skin allergy; skin bruising; skin defect; skin irritation; skin manifestation; sprain; sun exposure; tenosynovitis; thigh; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross Reactions; Dermatitis, Allergic Contact; Diclofenac; Flufenamic Acid; Humans; Ketoprofen; Male; Patch Tests; Thigh
Type
letter